Researcher
Erik Teugels
- Keywords:Medicine, General and logistic services
- Disciplines:Natural sciences
Affiliations
- Laboratory for Medical and Molecular Oncology (Research group)
Member
From1 Jan 2010 → Today - Clinical sciences (Department)
Member
From8 Apr 2019 → 31 Jan 2022 - Clinical sciences (Department)
Member
From1 Jan 2014 → 31 Jan 2022 - Department of Embryology and Genetics (Department)
Member
From1 Apr 1995 → 31 Dec 2013 - LW Academic Unit (Office)
Member
From1 Oct 1991 → 31 Mar 1995
Publications
1 - 10 of 46
- Exploiting genomic vulnerabilities in lung cancer for therapeutic targetting(2022)
Authors: Philippe Giron, Jacques De Grève, Ilse Rooman, Gustavo J Gutierrez, Erik Teugels
Number of pages: 188 - Targeting USP13 mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in Non-Small Cell Lung Cancer(2021)
Authors: Philippe Giron, Carolien Eggermont, Maxim Noeparast, Hugo Vandenplas, Erik Teugels, Ramses Forsyth, Olivier De Wever, Pedro Aza-Blanc, Gustavo J Gutierrez, Jacques De Grève
Pages: 2579-2593 - The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History(2020)
Authors: Sacha Mignon, Karen Willard-Gallo, Gert Van den Eynden, Roberto Salgado, Lore Decoster, Koen M Marien, Johan F Vansteenkiste, Erik Teugels, Jacques De Grève
Pages: 1221-1228 - Correction to(2020)
Authors: Gang Chen, Peter Kronenberger, Erik Teugels, Ijeoma Umelo, Jacques De Grève
- CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition(2019)
Authors: Maxim Noeparast, Philippe Giron, Alfiah Noor, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Carolien Eggermont, Hugo Vandenplas, Bram Boeckx, Diether Lambrechts, Jacques De Grève, et al.
Pages: 5933-5941 - The clinical characteristics of breast cancers with a familial risk in which no BRCA1/2 mutations were found are sometimes suggestive for a genetic etiology(2019)
Authors: Sofie Joris, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Christel Fontaine, Maryse Bonduelle, Pauwels Ingrid, Erik Teugels, Jacques De Grève
- Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families(2019)
Authors: Rajendra Bahadur Shahi, Sylvia De Brakeleer, Ben Caljon, Ingrid Pauwels, Maryse Bonduelle, Sofie Joris, Christel Fontaine, Marian Vanhoeij, Sonia Van Dooren, Erik Teugels, et al.
- Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer(2018)
Authors: Alfiah Noor, Ijeoma Umelo, Peter Kronenberger, Philippe Giron, Elly De Vlieghere, Olivier De Wever, Erik Teugels, Jacques De Grève
Pages: 28731-28744 - Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer(2018)
Authors: Maxim Noeparast, Philippe Giron, Sylvia De Brakeleer, Carolien Eggermont, Ulrike De Ridder, Erik Teugels, Jacques De Grève
Pages: 16110-16123 - The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant(2018)
Authors: Setareh Moghadasi, Huong D Meeks, Maaike Pg Vreeswijk, Linda Am Janssen, Åke Borg, Hans Ehrencrona, Ylva Paulsson-Karlsson, Barbara Wappenschmidt, Christoph Engel, Andrea Gehrig, et al.
Pages: 15-20
Linked dataset
1 - 7 of 7
- Additional file 9: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 1: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 6: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 4: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 11: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 5: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 3: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)